Skip to content

US · YI · MEDICAL - DISTRIBUTION

111, Inc. (YI) intrinsic value and stock valuation

$2.36as of 2026-11-21 · Mkt cap 32.32M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

111, Inc. DCF and intrinsic value

InvestorsCraft values YI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from YI’s statements →

111, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Distribution Shanghai, SH 201203 111.com.cn

How the business is doing

Fiscal 2016–2025, USD

Revenue
$12.2B+8.3% 5y CAGRd
20162025
Net income
-$-16.84M
20162025
Free cash flow
$114.7M
20162025
Total equity
$214.6M-30.6% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$12.2B$14.4B$14.9B$13.5B$12.4B
Operating income-$-10.03M$2.11M-$-350.1M-$-371M-$-642.14M
Net income-$-16.84M-$-64.74M-$-392.69M-$-416.88M-$-669.81M
EPSd-$-1.94M-$-7.51M-$-46.58M-$-50.05M-$-80.8M
Operating cash flow$119.1M$263M-$-447.24M-$-23.15M-$-688.84M
Capital expenditure-$-4.45M-$-15.2M-$-9.82M-$-31.57M-$-62.69M
Free cash flow$114.7M$247.8M-$-457.07M-$-54.73M-$-751.53M
Total assets$2.2B$2.79B$3.09B$3.47B$3.15B
Total debt$217.7M$256.8M$443.2M$344.2M$491M
Net debt-$-343.93M-$-205.52M-$-160.29M-$-329.48M-$-170.38M
Total equity$214.6M$380.8M$276.1M$648.2M$848.7M
Cash and short-term investments$611.7M$462.3M$653.7M$879.5M$844M
Income statement
20252024202320222021
Revenue$12.2B$14.4B$14.9B$13.5B$12.4B
Cost of revenue$11.5B$13.6B$14.1B$12.7B$11.8B
Gross profit$703.7M$829.2M$849M$840M$621.1M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$655M$384.8M$672.6M$663.5M$720.1M
Other expenses$58.8M$442.3M$526.5M$547.5M$543.1M
Operating expenses$713.7M$827.1M$1.2B$1.21B$1.26B
Cost and expenses$12.2B$14.4B$15.3B$13.9B$13.1B
Interest income$3.78M$7.04M$8.83M$8.12M$9.78M
Interest expense$34.6M$28.3M$20.1M$13.4M$5.49M
Depreciation and amortization$11.8M$17M$21.8M$40.8M$27.2M
Ebitda$1.81M$24.6M-$-311.26M-$-321.81M-$-588.32M
Operating income-$-10.03M$2.11M-$-350.1M-$-371M-$-642.14M
Total other income/expenses, net-$-11.86M-$-22.79M-$-3.08M-$-5.07M$21.1M
Income before tax-$-21.89M-$-20.68M-$-353.18M-$-376.07M-$-621.02M
Income tax expense$10K$100K$250K$0.00$0.00
Net income-$-16.84M-$-64.74M-$-392.69M-$-416.88M-$-669.81M
Weighted average shares outstanding$8.7M$8.62M$8.43M$8.33M$8.29M
Weighted average diluted shares outstanding$8.7M$8.62M$8.43M$8.33M$8.29M
Balance sheet
20252024202320222021
Cash and short-term investments$611.7M$462.3M$653.7M$879.5M$844M
Net receivables$318.5M$630.7M$647.5M$600.5M$495.2M
Inventory$999.1M$1.39B$1.42B$1.5B$1.12B
Total current assets$2.13B$2.65B$2.93B$3.24B$2.8B
Property, plant and equipment, net$65.3M$122M$138.1M$212.4M$314.1M
Goodwill and intangible assets$870K$1.44M$2.26M$3.27M$4.91M
Long-term investments$0.00$0.00$2M$2M$3M
Total non-current assets$75.4M$138.1M$155.7M$238M$344.1M
Total assets$2.2B$2.79B$3.09B$3.47B$3.15B
Accounts payable$1.28B$1.72B$1.59B$1.76B$1.35B
Short-term debt$187.8M$201.3M$380.6M$243.7M$325.4M
Deferred revenue$0.00$185.9M$193.5M$323.6M$202.6M
Total current liabilities$1.95B$2.34B$2.75B$2.73B$2.13B
Long-term debt$30M$55.5M$62.6M$100.5M$165.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$32.2M$64.4M$67.9M$100.5M$167.2M
Capital lease obligations$30M$95.8M$105.2M$165.2M$231.4M
Total liabilities$1.99B$2.41B$2.81B$2.83B$2.3B
Common stock$60K$60K$60K$60K$60K
Retained earnings-$-3.95B-$-3.88B-$-3.82B-$-3.43B-$-3.01B
Accumulated other comprehensive income (loss)$72.7M$74.4M$72.5M$75.6M$59.4M
Total equity$214.6M$380.8M$276.1M$648.2M$848.7M
Total investments$50.1M$0.00$52.1M$207.9M$185.6M
Total debt$217.7M$256.8M$443.2M$344.2M$491M
Net debt-$-343.93M-$-205.52M-$-160.29M-$-329.48M-$-170.38M
Cash flow statement
20252024202320222021
Net income-$-22.52M-$-20.78M-$-353.43M-$-376.07M-$-621.02M
Depreciation and amortization$11.8M$17M$21.8M$40.8M$27.2M
Stock-based compensation$10.1M$20.2M$226.7M$162.1M$145.6M
Change in working capital$77.2M$192.7M-$-424.33M$44.5M-$-369.87M
Accounts receivable$170.7M$122M-$-49.9M-$-86.98M-$-242.4M
Inventory$387.1M$28.1M$59.6M-$-406.29M-$-400.55M
Accounts payable-$-439.06M$132.7M-$-176.74M$417.5M$274M
Net cash provided by operating activities$119.1M$263M-$-447.24M-$-23.15M-$-688.84M
Investments in property, plant and equipment-$-4.45M-$-15.2M-$-9.82M-$-31.57M-$-62.69M
Acquisitions, net$0.00$0.00$0.00-$-2.96M$100K
Net cash used for investing activities-$-53.72M$37.4M$151.7M-$-47.17M$60.1M
Common stock issued$740K$10K$220K$270K$2.92M
Common stock repurchased$0.00$0.00$0.00$0.00-$-5.89M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-21.19M-$-406.24M$206M$22.7M$74.3M
Net change in cash$43M-$-105.22M-$-93.24M-$-43.88M-$-557.86M
Cash at end of period$561.3M$518.3M$623.6M$716.8M$760.7M
Operating cash flow$119.1M$263M-$-447.24M-$-23.15M-$-688.84M
Capital expenditure-$-4.45M-$-15.2M-$-9.82M-$-31.57M-$-62.69M
Free cash flow$114.7M$247.8M-$-457.07M-$-54.73M-$-751.53M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About 111, Inc.

        Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.

        CEO
        Junling Liu
        Employees
        1.06K
        Beta
        0.63

        Explore

        Frequently asked questions

        What is the intrinsic value of 111, Inc. (YI)?

        111, Inc. (YI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is YI undervalued?

        YI trades at a price of $2.36 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.